SectorWire
SearchRegister
MenuClose

Kalshi develops GPU contracts for prediction markets

Business1 min read

Summary

An analysis on a gambling industry site said Kalshi is developing contracts linked to artificial-intelligence computing costs as it seeks to build a GPU market. It cited $158,000 in open interest across five venues and concerns about transparent pricing, while CME Group’s proposed GPU futures remain under CFTC review.

Kalshi plans to develop financial contracts tied to GPU rental prices, starting with prediction markets, according to Kalshi's October white paper.

Kalshi began trading rental-price contracts for five GPU models in March 2026, including Nvidia's H100, H200 and B200. It uses prices from compute index provider Ornn to settle contracts and published forward curves from its weekly and monthly prediction markets in July.

The white paper's authors said computing power lacks a widely accepted spot-price benchmark and a liquid forward market. They suggested that cloud providers, AI developers and chipmakers could contribute their knowledge of rental prices to the exchange.

Open interest in Nvidia H100 GPU perpetual futures amounted to $158,000 across five venues, analysis by derivatives specialist Luke Jacobi found. Former CFTC attorney Braden Perry also raised the risk that GPU suppliers might manipulate settlement prices for contracts they trade.

Kalshi's longer-term proposals include perpetual and dated futures, as well as electricity derivatives intended to help businesses hedge infrastructure costs. Its sports and election contracts have been subject to gambling-law disputes.

CME Group has given the CFTC until January 2027 to examine its planned GPU futures, on condition that no other exchange launches comparable contracts before then.

Request a correction

Flag an issue

Keep reading

Regulation

Polymarket and Kalshi list health-related prediction contracts

Polymarket and Kalshi have begun listing contracts tied to health policy and clinical research, reportedly including markets on possible changes to US vaccine guidance. Kalshi spokesperson Dani Lever said clinical-trial and drug-approval markets may improve transparency in drug development, while Rutgers professor Lia Nower called for stronger government oversight; critics warned trading could affect trial behaviour.

Polymarket and Kalshi are reportedly offering health-related prediction contracts. The contracts include bets on whether the US Centers for Disease Control and Prevention will change its vaccine recommendations.

Continue reading